<p>A rigorous review of Crohn's pharmacotherapy, highlighting the "Do Nots": antibiotics and 5-ASAs have limited to no role in luminal disease. We explore the "Treat to Target" approach and the decision tree for Therapeutic Drug Monitoring (TDM) when patients lose response. The episode also covers perioperative washout periods for biologics and the landmark LIR!C trial, which validates early resection as a primary alternative to medical therapy for limited ileitis.</p>
